Bilcare Academy Event to Kick Off

“Bilcare Academy” Event to Kick Off Contract Pharma’s 15th Annual Contracting and Outsourcing Conference in September

Bilcare Research experts to deliver featured presentation: “The Role of Packaging Materials in Pharmaceutical Product Stability”

Bilcare Research Inc., one of the world’s largest manufacturers of blister packaging solutions, will host an educational event, dubbed Bilcare Academy, covering a range of topics dealing with the crucial role that packaging plays in the pharmaceutical life cycle. The event will take place at the Hyatt Regency in New Brunswick, NJ on September 21 – a day before the 15th Annual Contract Pharma Contracting and Outsourcing Conference & Tabletop Exhibition.

Bilcare Academy will entail in-depth discussions concerning the use of scientific models in packaging design to expedite the development process and overcome existing resource challenges, as well as a special 11:00am luncheon presentation, titled “The Role of Packaging Materials in Pharmaceutical Product Stability.”
To register for Bilcare Academy, contact Bilcare Research by emailing Chuck.Newswanger@bilcare.com, or calling (302) 256-7089.


Among other topics, industry packaging experts will discuss trends in high-barrier blister materials, consideration of sustainability in pharmaceutical packaging, and the company’s groundbreaking methods for streamlining paths to optimum product packaging.

Meet the Bilcare Research Global Pharma Team at Pharmapack Europe Booth 841| Porte de Versailles | Paris | France

The Global Pharma Team will be exhibiting for the 4th year in a row at the Pharmapack in Paris. Bilcare will share the latest developments in its offer to the pharmaceutical packaging market. Besides packaging materials itself, Bilcare  offers its expertise in packaging design and drug delivery systems fitting to patients’ needs

http://www.bilcaresolutions.com/upload/media/media/1/Bilcare_Reasearch_at_Pharmapack_Europe_PR_EN_020316%5B571%5D.pdf

Bilcare Research Segregates Pharma-Related Production Operations

Bilcare Research Inc., a division of one of the world’s largest manufacturers of blister packaging solutions, has begun segregating pharma-related production operations from those servicing other industries at its Wilmington, DE facility. The decision showcases Bilcare‘s commitment to the pharmaceutical sector amid growing customer demand and heightened quality control expectations.
Part of the global Pharmaceutical Packaging Innovation (PPI) Business Unit of Bilcare Research AG,   Bilcare Research offers a variety of mono and barrier blister films to the pharmaceutical packaging industry.  In addition to manufacturing pharmaceutical blister films, the company also produces products for other business units of the company.

With growing customer demand and a steadily increasing market share in the pharmaceutical films sector, Bilcare’s effort to separate its PPI production and storage area from areas servicing other businesses has the purpose of clearly differentiating its production process along industry-specific lines.  The result is the ability to service all sectors more efficiently.

Distributional

“We are dedicated to our pharmaceutical customers and this is just one more example of how,” said Kevin Stevens, President and Managing Director of Bilcare Research Inc. “Our strategy is to exceed our customers’ expectations in the quality of Bilcare’s products; the new plant layout shows our commitment and investment to that end. Packaging pharmaceutical products in an ideal fashion calls for a dedicated, siloed production environment throughout the supply chain, and we aim to set the bar high toward that goal.”

Bilcare Pharma Packaging Strategy

Packaging is defined as the collection of different components which surround the pharmaceutical product from the time of production until its use. Pharma packaging products is a broad, encompassing, and multi-faceted task. At Bilcare Packaging is responsible for providing life-saving drugs, medical devices, medical treatments, and new products like medical nutritionals in every imaginable dosage form to deliver every type of supplement, poultice, liquid, solid, powder, suspension, or drop to people the world over. It is transparent to the end user when done well and is open to criticism from all quarters when done poorly.

Distribution of products is now more global than ever. Mass customization of packaging to permit its use in multiple markets is a topic that needs exposition and discussion. Environmental issues, including sustainability, will always be a subjective dimension to any packaging design. Pharma Packaging is an emerging science, an emerging engineering discipline, and a success contributor to pharmaceutical industries.

Packaging can reside, or report through research and development (R and D), engineering, operations, purchasing, marketing, or the general administrative department of a company. For the majority of products produced in Bilcare it is probably the single largest aggregate purchase made by a company of materials critical to the protection, distribution, and sale of the product.

Dr. A P J Abdul Kalam at the 43rd Annual General Meeting of OPPI.

Highlights of Dr. A P J Abdul Kalam comments on Innovative Packaging at the 43rd Annual General Meeting of OPPI.

Visit : http://www.bilcare.com/insight/dimensions_of_healthcare.htm

Empowering Consumers to make Safer Buying Decisions : nonClonableID Technologies

With breakthrough research and development in nanotechnology and an emphasis on creating a cost-effective solution, Bilcare has created a first-of-its-kind nonClonableID™ Authentication Technology. Bilcare Technologies is a comprehensive response to counterfeiting and an indispensable tool for building confidence in consumers. Find out how our unique technology provides an increased degree of security and empowers consumers to authenticate a product in real-time.

nonClonableID Technologies

Bilcare Technologies is a research and technology leader focused on creating next-generation anti-counterfeiting, security and brand protection solutions for a broad range of industry sectors.

Bilcare Technologies is a business unit of Bilcare Ltd. - an innovation-led solutions provider that partners with the global pharmaceutical and healthcare industry to improve patient healthcare outcomes.

With breakthrough research and development in micro and nanotechnology, Bilcare Technologies has developed a first-of-its-kind technology - nonClonableID™. The solution enables products to be authenticated as they move through the supply chain to the end consumer.

India, Bilcare Technologies combines its innovative approach with in-depth business knowledge in brand protection and supply chain integrity to offer solutions tailored to varying client requirements.

We are firmly committed to helping our clients accomplish their business goals while protecting their brands against counterfeiting. With its affordability, security and ease of use, nonClonableID™ is a potent tool for the global economy in its fight against counterfeiting.

About nonClonableID

Bilcare’s nonClonableID™ comprises of a unique fingerprint that can be seamlessly integrated with products, ID cards and documents to provide a totally secure and reliable identification and authentication solution.

nonClonableID™ employs unique materials-based fingerprints that are prohibitively difficult to copy. These tamper-evident fingerprints are irreproducible and cannot be duplicated even by Bilcare.

Features of nonClonableID™

• Unique fingerprints generated out of randomly distributed micro and nano particles
• Machine-readable fingerprints enable an objective and reliable authentication process
• Real-time authentication through hand-held portable readers
• Fingerprints can be integrated with overt systems like barcodes/ RFID tags etc. and within any existing software/hardware infrastructure
• Proprietary scanning device scans the fingerprint and instantly communicates the encrypted information with a secure server through mobility platforms such as GPRS, 3G or Broadband.
• Complete authentication report on a mobile or computer using robust web enterprise secured applications and data management at back-end.

Bilcare GCS Expands Pre-Clinical and Early-Stage Development Capabilities

PHOENIXVILLE, Pa — November, 2008 — In its endeavor to accelerate the development process cycle resulting in enhanced “Speed to Market” for its clients, Bilcare Global Clinical Supplies, a leading single-source provider of Clinical Trial Supplies and services, endorses its continual capability enhancement commitment by supplementing its ability of developing functionally viable and innovative formulation dosage forms for pre-clinical and early-phase drugs.

Vincent Santa Maria, President – Bilcare GCS, Americas stated that as part of a major capital investment program at its facilities in the U.S., Bilcare GCS has added sophisticated fluid bed granulation and enhanced capsule filling technologies to its R&D Center. “With this upgrade, Bilcare GCS can now quickly produce a wider variety of drug dosage forms with high product quality at par industry benchmark. These investments in R&D services further prove our commitment to being a full-service partner to our global customers with the offering of a wide breath of specialty services, continues Vincent.”

This capability enhancement compliments the increasing number of investigational new drug (IND) applications by innovator pharma and Biotech companies, which in turn requires multi-pronged expertise, more particularly in the Formulation and Analytical research and development, commented Praful Naik, Ph.D., Chief Scientific Officer, Bilcare Limited.

The fluid-bed granulation technology extends Bilcare’s solid dosage formulation capabilities. The granulation system equipped with Wurster coating inserts enables Bilcare to develop and deliver specialized coating processes for granules and non-pareils with high precision and consistency for creation of top quality sustained and controlled-release tablet and capsule formulations.

The In-Cap® capsule system, capable of filling several thousand capsules per hour in multiple permutations, is a versatile tool for pre-clinical and early-stage development. This equipment extends both development and clinical manufacturing capabilities for a myriad of formulation types including powders, pellets, tablets and liquids.

“Bilcare’s R&D center can now develop a broad array of dosage forms with innovative delivery mechanisms, which exceeds those developed by pharmaceutical companies,” says Frank Santillo, Ph.D., Bilcare GCS’ senior director for research services. “Most importantly, we have the expertise to take a drug candidate from concept to clinical production without the client suffering critical and costly delays as a result of hand-offs, continues Frank”

About Bilcare Global Clinical Supplies

Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services, and complete project management. Its services for solid, semi-solid, liquid, DEA (CI-V), and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, manufacturing, analytical services and clinical supplies packaging and labeling, to IVRS, QP services, controlled temperature (cold chain) CTM storage, worldwide distribution, and returns and destructions accountability.